mycophenolate (Cellcept, Myfortic)

^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13]^[14]

Introduction

Mycophenolate mofetil. Antibiotic substance produced by Penicillium brevi-compactum, P. stoloniferum & related species.

Medication Guide to be distributed to every patient who fills a CellCept prescription.^[7]

Indications

maintenance of immunosuppression after organ transplantation & for treatment of refractory rejection
- renal graft rejection
- liver transplantation^[12]
used in conjunction with corticosteroids & cyclosporine
use in suppressing need for azathioprine
treatment of systemic lupus erythematosus, especially lupus nephritis^[11]
polymyositis, dermatomyositis, vasculitis

Contraindications

pregnancy, pregnancy category: D^[1]^[4]^[6]
women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within one week prior to beginning therapy
women of childbearing potential taking mycophenolate must
- receive contraceptive counseling
- use effective contraception
begin using 2 chosen methods of contraception 4 weeks prior to starting mycophenolate therapy, unless abstinence is the chosen method
contraceptives should be used during & for 6 weeks after stopping mycophenolate

pregnancy category = x

Dosage

1 g PO BID
take on an empty stomach
do not crush or chew capsules
dose should be decreased or stopped in patients with neutropenia < 1300/mm3

Tabs: 250 mg. Myfortic: enteric coated

Storage

must be protected from light
product labeling for U.S. products does not instruct to dispense in original container^[13] Dosage adjustment with renal failure:
doses > 2 g/day are not recommended

Monitor

baseline CBC, LFTs, serum creatinine
thereafter CBC, LFTs, serum creatinine every 3 months^[1]

monitor with immunosuppressive agents

Adverse effects

commmon > 10%
- general
  - abdominal pain, fever, headache, infection from immunosuppression, asthenia, chest pain, back pain, hypertension
- central nervous system
  - tremor, insomnia, dizziness
- dermatology
  - acne, rash
- gastrointestinal
  - diarrhea, constipation, dyspepsia, nausea/vomiting
- hematologic
  - hypochromic anemia, leukopenia, thrombocytopenia, leukocytosis
  - pure red cell aplasia^[9]^[10]
- metabolic
  - peripheral edema, hypercholesterolemia, hypophosphatemia, edema, hypokalemia, hyperkalemia, hyperglycemia
- respiratory
  - dyspnea, cough, pharyngitis, bronchitis, pneumonia
- urogenital
  - UTI, hematuria, renal tubular necrosis
progressive multifocal leukoencephalopathy ?^[5]
congenital anomalies following exposure to mycophenolate mofetil during pregnancy, including microtia, cleft lip & cleft palate^[6]
BK virus-associated nephropathy in renal transplant patients^[8]

Caution:

avoid inhalation or direct contact with skin or mucous membranes of powder in capsules; wash with soap & water if occurs
capsules should not be opened or crushed
teratogenic^[6]

drug adverse effects of immunosuppressive agents

Drug interactions

antacids decrease absorption
cholestyramine decreases absorption
mycophenolate may increase levels of
- acyclovir
- ganciclovir
iron supplements may increase mycophenolate levels
probenecid may increase mycophenolate levels
salicylates may increase free fraction of mycophenolate

Mechanism of action

immunosuppressive agent
inhibits purine metabolism
- inhibits inosine monophosphate dehydrogenase
- antiproliferative
  - preferentially inhibits T-cells & B-cells^[1]

More general terms

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 17. American College of Physicians, Philadelphia 1998, 2015
↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
↑ Department of Veterans Affairs, VA National Formulary
↑ ^4.0 ^4.1 Prescriber's Letter 14(12): 2007 Pregnancy Category Change for Mycophenolate Motefil (CellCept) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=231208&pb=PRL (subscription needed) http://www.prescribersletter.com
↑ ^5.0 ^5.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#mycophenolate
↑ ^6.0 ^6.1 ^6.2 ^6.3 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#MMF
↑ ^7.0 ^7.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2009/safety09.htm#CellCept
↑ ^8.0 ^8.1 FDA Medwatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm171828.htm
↑ ^9.0 ^9.1 FDA Medwatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm177397.htm
↑ ^10.0 ^10.1 FDA MedWatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm181306.htm
↑ ^11.0 ^11.1 Kamanamool N, McEvoy M, Attia J et al Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010 Jul;89(4):227-35. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20616662
↑ ^12.0 ^12.1 Deprecated Reference
↑ ^13.0 ^13.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
↑ Myfortic: Novartis at (888) 669-6682

Database

[ref1-1] 1.0 ^1.1 ^1.2 ^1.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 17. American College of Physicians, Philadelphia 1998, 2015

[ref2-2] Kaiser Permanente Northern California Regional Drug Formulary, 1998

[ref3-3] Department of Veterans Affairs, VA National Formulary

[ref4-4] 4.0 ^4.1 Prescriber's Letter 14(12): 2007 Pregnancy Category Change for Mycophenolate Motefil (CellCept) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=231208&pb=PRL (subscription needed) http://www.prescribersletter.com

[ref5-5] 5.0 ^5.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#mycophenolate

[ref6-6] 6.0 ^6.1 ^6.2 ^6.3 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#MMF

[ref7-7] 7.0 ^7.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2009/safety09.htm#CellCept

[ref8-8] 8.0 ^8.1 FDA Medwatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm171828.htm

[ref9-9] 9.0 ^9.1 FDA Medwatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm177397.htm

[ref10-10] 10.0 ^10.1 FDA MedWatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm181306.htm

[ref11-11] 11.0 ^11.1 Kamanamool N, McEvoy M, Attia J et al Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010 Jul;89(4):227-35. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20616662

[ref12-12] 12.0 ^12.1 Deprecated Reference

[ref13-13] 13.0 ^13.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com

[ref14-14] Myfortic: Novartis at (888) 669-6682

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

mycophenolate (Cellcept, Myfortic)

Contents

Introduction

Indications

Contraindications

Dosage

Storage

Monitor

Adverse effects

Drug interactions

Mechanism of action

More general terms

References

Database

Navigation menu

mycophenolate (Cellcept, Myfortic)

Introduction

Indications

Contraindications

Dosage

Storage

Monitor

Adverse effects

Drug interactions

Mechanism of action

More general terms

References

Database

Navigation menu

Search